Common Cold Market

Common Cold Market Report and Forecast 2024-2032

The common cold market was valued at USD 8.3 billion in 2023 driven by increasing incidence of common cold and growing preventive healthcare products across the 8 major markets. It is expected to grow at a CAGR of 8.7% during the forecast period 2024-2032 and attain a market value of USD 18.7 billion by 2032.

Common Cold Market Analysis

The common cold is a viral infection that primarily affects the upper respiratory tract, causing symptoms such as a runny nose, cough, sneezing, sore throat, and congestion. It is usually caused by rhinoviruses and is highly contagious, spreading through respiratory droplets or direct contact. Although the common cold is typically mild and self-limiting, it can cause discomfort and lead to secondary infections in some cases. Treatments focus on symptom relief, with a range of over-the-counter medications available, including antihistamines, decongestants, and expectorants.

Market Drivers

  • High Prevalence of the Common Cold: The common cold is one of the most frequent human illnesses, affecting millions worldwide each year. Its widespread prevalence continues to drive demand for over-the-counter medications that alleviate symptoms and improve patient comfort.
  • Increased Consumer Awareness of Cold Relief Products: With the growing awareness of health and wellness, consumers are more proactive in seeking treatment for cold symptoms. This trend drives demand for various remedies, including natural supplements and OTC medications, contributing to market expansion.
  • Rise in Self-Medication Practices: Consumers are increasingly turning to self-medication for common cold symptoms, especially in regions with easy access to over-the-counter medications. This shift towards self-care contributes to the growing demand for cold relief products.
  • Growing Healthcare Expenditure: Increasing healthcare expenditure globally, particularly in emerging markets, is improving access to treatments for common illnesses like the cold. This expanded access to prescription and OTC medications boosts the demand for cold remedies.
  • Expansion of E-Commerce Channels: The rise of e-commerce platforms is making it easier for consumers to purchase medications for cold relief online. This trend is particularly pronounced in the wake of the COVID-19 pandemic, which has accelerated the shift towards digital health and online pharmacies.
Challenges
  • Side Effects of Cold Medications: Some cold medications, particularly antihistamines and decongestants, can cause unwanted side effects such as drowsiness, dizziness, or increased heart rate. These side effects may deter consumers from using certain products or lead to concerns about safety.
  • High Competition from Natural Remedies: There is increasing competition from natural and homeopathic remedies that claim to offer relief from cold symptoms. These alternatives often appeal to health-conscious consumers, who may prefer herbal supplements or natural treatments over traditional pharmaceuticals.
  • Regulatory Restrictions on Cold Medications: The regulation of cold medications, particularly for over-the-counter products, can vary by region. In some cases, restrictions on the sale of decongestants or other ingredients limit access to certain products, creating challenges for manufacturers and distributors.
  • Seasonal Nature of the Common Cold: The common cold is highly seasonal, with most cases occurring during the colder months. This seasonal nature can lead to fluctuations in demand for cold medications, making it difficult for manufacturers to maintain consistent sales throughout the year.
Future Opportunities
  • Development of Combination Therapies: There is growing interest in combination therapies that provide multi-symptom relief for the common cold. These products, which combine antihistamines, decongestants, and pain relievers, offer a convenient solution for consumers and present opportunities for product innovation.
  • Expansion into Emerging Markets: Emerging markets in Asia Pacific and Latin America present significant growth opportunities for common cold medications. As healthcare infrastructure improves and disposable income rises, more consumers in these regions are gaining access to OTC cold remedies.
  • Increased Demand for Natural and Herbal Products: The rising consumer preference for natural and herbal treatments is creating opportunities for the development of cold medications that incorporate plant-based ingredients. These products appeal to health-conscious consumers seeking gentler, more natural remedies.
  • Technological Advances in Drug Delivery: Innovations in drug delivery, such as fast-dissolving tablets and extended-release formulations, are providing new opportunities for cold medications. These technologies offer more convenient dosing options and can improve patient adherence to treatment regimens.
  • Growth of Online Pharmacies: The increasing popularity of online pharmacies presents opportunities for manufacturers to expand their distribution networks. By offering cold medications through e-commerce platforms, companies can reach a broader customer base and cater to the growing demand for convenient, home-delivered healthcare products.
Common Cold Market Trends

The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
  • Shift Towards Natural and Organic Products
Consumers are increasingly seeking natural and organic remedies to treat common cold symptoms. Products containing herbal ingredients such as echinacea, elderberry, and ginger are gaining popularity, as they are perceived to be safer and gentler than synthetic medications. This growing demand for plant-based and holistic treatments is driving the expansion of the natural remedies segment within the common cold market.
  • Increasing Use of Combination Cold Medications
There is a growing trend toward combination cold medications that address multiple symptoms—such as congestion, cough, and fever within a single product. Consumers prefer these multi-symptom solutions for their convenience and effectiveness. The development of combination therapies is expected to grow, as they offer improved symptom relief and reduce the need for multiple medications.
  • Growth in Preventive Health Measures
More consumers are turning to preventive health products, such as supplements that boost immune function, to reduce the risk of contracting common colds. Vitamins like C and D, zinc supplements, and probiotics are increasingly being marketed as ways to strengthen the immune system. This trend is contributing to the rise of immune-boosting products as a complementary segment in the common cold market.
  • Expansion of E-Commerce and Online Pharmacies
The growing popularity of e-commerce and online pharmacies is transforming how consumers access common cold medications. With the convenience of home delivery and 24/7 availability, online platforms have become a key distribution channel, especially after the COVID-19 pandemic. This trend is expected to continue, with manufacturers investing in digital sales strategies to reach a broader audience.
  • Increasing Demand for Convenient and Fast-Acting Formulations
Consumers are seeking faster relief from cold symptoms, driving demand for formulations such as fast-dissolving tablets, nasal sprays, and lozenges. These products offer rapid symptom relief and are easy to use, making them particularly attractive to busy individuals. The focus on convenience and quick action is expected to lead to more innovation in drug delivery systems for cold medications.
  • Rising Focus on Innovative Packaging
Packaging innovations, such as blister packs, single-dose sachets, and resealable pouches, are becoming more prevalent in the common cold market. These packaging solutions provide greater portability, longer shelf life, and ease of use for consumers. The focus on user-friendly, portable packaging is helping manufacturers differentiate their products in a competitive market, enhancing brand appeal.

Common Cold Market Segmentation

Market Breakup by Drug Class
  • Antihistamines
  • Expectorants
  • Bronchodilators
  • Decongestants
  • Antibiotics
  • Others
The market is segmented into antihistamines, expectorants, bronchodilators, decongestants, antibiotics, and others. Antihistamines and decongestants remain the leading categories, driven by their effectiveness in alleviating cold symptoms such as nasal congestion and sneezing. Expectorants and bronchodilators are commonly used to manage respiratory symptoms like coughing. Antibiotics are prescribed only for secondary bacterial infections, while the other category includes various OTC remedies, such as herbal supplements.

Market Breakup by Doses
  • Oral Syrups
  • Tablets/Pills
  • Nasal Drops
  • Others
The market is divided into oral syrups, tablets/pills, nasal drops, and others. Tablets and pills are the most popular dosage forms due to their ease of use, widespread availability, and precise dosing. Oral syrups are particularly popular for children and individuals who struggle with swallowing pills. Nasal drops are effective for immediate relief of nasal congestion, while other dosage forms include lozenges and inhalers for symptom management.

Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Independent Pharmacies
  • Online Pharmacies
  • Others
The common cold medication market is segmented into hospital pharmacies, independent pharmacies, online pharmacies, and others. Independent pharmacies remain the dominant distribution channel due to accessibility and consumer trust. However, online pharmacies are gaining market share due to the convenience of home delivery and the growing trend of e-commerce in healthcare. Hospital pharmacies are significant in prescribing treatments for more severe cases requiring professional consultation.

Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India
The market is segmented into the United States, EU-4 and the United Kingdom (Germany, France, Italy, Spain, and the UK), Japan, and India. The United States and Europe lead the market due to high healthcare expenditure, advanced healthcare infrastructure, and a well-established market for over-the-counter cold medications. Emerging markets like India and Japan are expected to grow rapidly, driven by rising consumer awareness, improved access to healthcare, and increased demand for cold relief products.

Common Cold Market Competitive Landscape

The competitive landscape of the common cold market includes key players such as Reckitt Benckiser Group PLC, Johnson & Johnson, GSK plc, Novartis AG, Bayer AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Procter & Gamble Health Limited, Sanofi, and Haleon Group. These companies focus on continuous innovation in product formulations, including the development of multi-symptom remedies and natural alternatives. Strategic partnerships, mergers, and acquisitions are common strategies to expand market share and strengthen product portfolios. The increasing focus on e-commerce and digital marketing is helping these firms reach a wider consumer base, particularly in emerging markets.

Key Questions Answered in the Report
  • What are the major drivers contributing to the growth of the common cold market?
  • How is the shift towards natural and organic products impacting the common cold market?
  • What are the primary challenges faced by manufacturers in developing effective cold treatments?
  • How is the rise of online pharmacies influencing the distribution of cold relief products?
  • What are the trends driving the demand for combination therapies in cold medications?
  • How are e-commerce and digital channels reshaping the sales of cold medications?
  • What opportunities exist for pharmaceutical companies in emerging markets for cold treatments?
  • How are innovative drug delivery systems improving convenience and patient adherence?
  • What are the implications of seasonal demand fluctuations on the common cold market?
  • How are competitive strategies such as mergers and partnerships shaping the common cold market?
  • What is the role of preventive health products in the common cold treatment landscape?
  • How are regulatory frameworks affecting the availability and distribution of cold medications?
Key Benefits for Stakeholders

The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the common cold market from 2017-2032.

The research report provides the latest information on the market drivers, challenges, and opportunities in the common cold market.

The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.

Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the common cold industry and its attractiveness.

The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Common Cold Market Overview – 8 Major Markets
3.1 Common Cold Market Historical Value (2017-2023)
3.2 Common Cold Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Common Cold Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Common Cold Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 United Kingdom
7.1.1.3 EU-4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Diagnosed Cases, by Country
7.1.2.1 U.S.
7.1.2.2 United Kingdom
7.1.2.3 EU-4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate, by Country
7.1.3.1 U.S.
7.1.3.2 United Kingdom
7.1.3.3 EU-4
7.1.3.4 India
7.1.3.5 Japan
8 Common Cold Market Landscape – 8 Major Markets
8.1 Common Cold Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Common Cold Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Doses
9 Common Cold Market Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Common Cold Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Common Cold Market Segmentation (2018-2034) - 8 Major Markets
12.1 Common Cold Market (2018-2034) by Drug Class
12.1.1 Market Overview
12.1.2 Antihistamines
12.1.3 Expectorants
12.1.4 Bronchodilators
12.1.5 Decongestants
12.1.6 Antibiotics
12.1.7 Others
12.2 Common Cold Market (2018-2034) by Doses
12.2.1 Market Overview
12.2.2 Oral Syrups
12.2.3 Tablets/Pills
12.2.4 Nasal Drops
12.2.5 Others
12.3 Common Cold Market (2018-2034) by Distribution Channel
12.3.1 Market Overview
12.3.2 Hospital Pharmacies
12.3.3 Independent Pharmacies
12.3.4 Online Pharmacies
12.3.5 Others
12.4 Common Cold Market (2018-2034) by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Common Cold Market (2018-2034)
13.1 United States Common Cold Market Historical Value (2017-2023)
13.2 United States Common Cold Market Forecast Value (2024-2032)
13.3 United States Common Cold Market (2018-2034) by Drug Class
13.3.1 Market Overview
13.3.2 Antihistamines
13.3.3 Expectorants
13.3.4 Bronchodilators
13.3.5 Decongestants
13.3.6 Antibiotics
13.3.7 Others
13.4 United States Common Cold Market (2018-2034) by Doses
13.4.1 Market Overview
13.4.2 Oral Syrups
13.4.3 Tablets/Pills
13.4.4 Nasal Drops
13.4.5 Others
13.5 United States Common Cold Market (2018-2034) by Distribution Channel
13.5.1 Market Overview
13.5.2 Hospital Pharmacies
13.5.3 Independent Pharmacies
13.5.4 Online Pharmacies
13.5.5 Others
14 EU-4 and United Kingdom Common Cold Market (2018-2034)
14.1 EU-4 and United Kingdom Common Cold Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Common Cold Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Common Cold Market (2018-2034) by Drug Class
14.3.1 Market Overview
14.3.2 Antihistamines
14.3.3 Expectorants
14.3.4 Bronchodilators
14.3.5 Decongestants
14.3.6 Antibiotics
14.3.7 Others
14.4 EU-4 and United Kingdom Common Cold Market (2018-2034) by Doses
14.4.1 Market Overview
14.4.2 Oral Syrups
14.4.3 Tablets/Pills
14.4.4 Nasal Drops
14.4.5 Others
14.5 EU-4 and United Kingdom Common Cold Market (2018-2034) by Distribution Channel
14.5.1 Market Overview
14.5.2 Hospital Pharmacies
14.5.3 Independent Pharmacies
14.5.4 Online Pharmacies
14.5.5 Others
15 Japan Common Cold Market
15.1 Japan Common Cold Market Historical Value (2017-2023)
15.2 Japan Common Cold Market Forecast Value (2024-2032)
15.3 Japan Common Cold Market (2018-2034) by Drug Class
15.3.1 Market Overview
15.3.2 Antihistamines
15.3.3 Expectorants
15.3.4 Bronchodilators
15.3.5 Decongestants
15.3.6 Antibiotics
15.3.7 Others
15.4 Japan Common Cold Market (2018-2034) by Doses
15.4.1 Market Overview
15.4.2 Oral Syrups
15.4.3 Tablets/Pills
15.4.4 Nasal Drops
15.4.5 Others
15.5 Japan Common Cold Market (2018-2034) by Distribution Channel
15.5.1 Market Overview
15.5.2 Hospital Pharmacies
15.5.3 Independent Pharmacies
15.5.4 Online Pharmacies
15.5.5 Others
16 India Common Cold Market
16.1 India Common Cold Market Historical Value (2017-2023)
16.2 India Common Cold Market Forecast Value (2024-2032)
16.3 India Common Cold Market (2018-2034) by Drug Class
16.3.1 Market Overview
16.3.2 Antihistamines
16.3.3 Expectorants
16.3.4 Bronchodilators
16.3.5 Decongestants
16.3.6 Antibiotics
16.3.7 Others
16.4 India Common Cold Market (2018-2034) by Doses
16.4.1 Market Overview
16.4.2 Oral Syrups
16.4.3 Tablets/Pills
16.4.4 Nasal Drops
16.4.5 Others
16.5 India Common Cold Market (2018-2034) by Distribution Channel
16.5.1 Market Overview
16.5.2 Hospital Pharmacies
16.5.3 Independent Pharmacies
16.5.4 Online Pharmacies
16.5.5 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 India CDSCO
17.5 Japan PMDA
18 Patent Analysis
18.1 Analysis by Drug Class of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by Year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Distribution Channel
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Drug Class of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Drug Class of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Reckitt Benckiser Group PLC
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Company News and Development
23.2.5 Certifications
23.3 Johnson & Johnson
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Company News and Development
23.3.5 Certifications
23.4 GSK plc
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Company News and Development
23.4.5 Certifications
23.5 Novartis AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Company News and Development
23.5.5 Certifications
23.6 Bayer AG
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Company News and Development
23.6.5 Certifications
23.7 Sun Pharmaceutical Industries. Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Company News and Development
23.7.5 Certifications
23.8 Pfizer Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Company News and Development
23.8.5 Certifications
23.9 Procter & Gamble Health Limited
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Company News and Development
23.9.5 Certifications
23.10 Sanofi
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Company News and Development
23.10.5 Certifications
23.11 Haleon Group
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Company News and Development
23.11.5 Certifications
24 Common Cold Treatment Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings